The embodiment relates to a saliva reagent strip and, more particularly, to saliva reagent strip for visibly indicating the concentration of pepsin and/or pepsinogen in a salvia sample.
Pepsin is the principle digestive enzyme of the stomach. U.S. Pat. No. 5,879,897, the content of which is hereby incorporated by reference into this specification, discloses a diagnostic method for diagnosing esophageal and extraesophageal gastric reflux (EEGR) and gastroesophageal reflux disease (GERD) by detecting the presence of pepsin of subjects suspected of having a reflux disorder or disease.
U.S. Pat. No. 6,372,513, the content of which is hereby incorporated by reference, discloses a lateral flow test strip for diagnostic testing of oral fluids including saliva. However, such a test strip merely permits the saliva to migrate along the strip, moving the antibody-marker agents along the strip. A chemical reaction will occur only if the analyte is present in the test sample. Thus, a concentration of a particular enzyme in the saliva cannot be obtained or shown on the strip.
CN 105092563 discloses a chemiluminescence ELISA kit for detecting pepsase. However, such detection requires the use of additional equipment such as a microplate reader with chemiluminescence capability (luminometer) to measure the light produced.
Thus, there is a need to provide a reagent test strip to determine and visually show a concentration of pepsin and/or pepsinogen in a saliva sample without the need for additional analysis or equipment.
An objective of the embodiment is to fulfill the need referred to above. In accordance with the principles of an embodiment, this objective is achieved by a reagent strip for determining a concentration of an analyte in a saliva sample. The reagent strip includes a sample receiving portion having a detector reagent thereon. The sample receiving portion includes at least one indicator constructed and arranged to indicate a specific concentration of the analyte in a saliva sample. The strip is constructed and arranged such that when the saliva sample is introduced onto the sample receiving portion, a chemical reaction occurs if the analyte is present in the saliva sample and the indicator will activate if a specific concentration of the analyte is present within the saliva sample so as to indicate the specific concentration.
In accordance with another aspect of an embodiment, a kit includes a plurality of reagent strips for determining a concentration of an analyte in a saliva sample. Each reagent strip includes a sample receiving portion having a detector reagent thereon. The sample receiving portion includes an indicator constructed and arranged to indicate a specific concentration of the analyte in a saliva sample. The indicator of each strip is different from indicators of other strips of the plurality of strips for detecting different concentrations the analyte. Each strip is constructed and arranged such that when the saliva sample is introduced onto the conjugate pad, a chemical reaction occurs if the analyte is present in the saliva sample and the indicator will activate if a specific concentration of the analyte is present within the saliva sample.
With reference to
To test a saliva sample with the reagent strip 10, the saliva sample (saliva alone or with a buffer or other amplifier) is introduced onto the sample receiving portion 12 wherein a chemical reaction begins if the analyte is present in the sample. The sample migrates to the capture zones 14 and based on the concentration of the analyte, the corresponding capture zones 14 will activate indicators 16 (vertical lines) that indicate specific concentrations of the analyte within the sample. In the embodiment of
Thus, with the strip 10 or kits 18 of the embodiments, advantageously, concentration of an analyte in a saliva sample is readily visible to a user without the need for additional processing or machines. The ability to obtain a quantitative value of the concentration of pepsin or pepsinogen in a saliva sample with strip 10 or kits 18 enables one to match a disease or symptoms with such concentration.
The foregoing preferred embodiments have been shown and described for the purposes of illustrating the structural and functional principles of the present invention, as well as illustrating the methods of employing the preferred embodiments and are subject to change without departing from such principles. Therefore, this invention includes all modifications encompassed within the spirit of the following claims.
Number | Date | Country | |
---|---|---|---|
62659728 | Apr 2018 | US |